Skip to main content

Table 2 Characteristics of study patients

From: Estimated influence of a novel biocompatible dialysis membrane on vascular events in dialysis patients with diabetic nephropathy: a prospective randomized controlled pilot study

 

NV group

PS group

P value

Number of patients

15

15

–

Sex (male/female)

10/5

13/2

0.39

Age (years)

69.5 ± 7.8

67.6 ± 10.5

0.49

Duration of dialysis (years)

9.2 ± 3.9

9.1 ± 3.7

0.95

Insulin administration (Y/N)

6/9

7/8

0.71

Duration of diabetic nephropathy (years)

19.5 ± 10.7

16.5 ± 7.7

0.59

Administration of DPP-4 inhibitors (Y/N)

12/3

10/5

0.68

Administration of antihypertensive agents (Y/N)

13/2

11/4

0.65

Body weight (kg)

65.2 ± 12.9

62.6 ± 10.2

0.77

HbA1c (%)

6.2 ± 0.9

6.3 ± 0.9

0.88

Hb (g/dL)

10.4 ± 0.7

10.2 ± 0.5

0.55

Serum albumin (g/dL)

4.0 ± 0.4

3.9 ± 0.4

0.38

Surface area of dialyzer (m2)

1.9 ± 0.3

1.8 ± 0.4

0.34

  1. Results of parameters were evaluated in enrolled patients and are presented as the mean ± standard deviation